QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NASDAQ:CLVS

Clovis Oncology - CLVS Stock Forecast, Price & News

$1.24
-0.06 (-4.62%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.19
$1.30
50-Day Range
$1.05
$1.74
52-Week Range
$0.58
$4.76
Volume
1.44 million shs
Average Volume
9.58 million shs
Market Capitalization
$179.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.88

Clovis Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
293.1% Upside
$4.88 Price Target
Short Interest
Bearish
22.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.47mentions of Clovis Oncology in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$6,822 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.74) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

674th out of 1,072 stocks

Pharmaceutical Preparations Industry

322nd out of 534 stocks

CLVS stock logo

About Clovis Oncology (NASDAQ:CLVS) Stock

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Why Is Clovis Oncology (CLVS) Stock Up Today?
Why Is Clovis Oncology (CLVS) Stock Down 10% Today?
Recap: Clovis Oncology Q2 Earnings
EMA recommends restricted use of Clovis cancer drug
Why Clovis Oncology Stock Trounced the Market Today
See More Headlines
Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Company Calendar

Last Earnings
8/08/2022
Today
10/05/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.88
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$4.75
Forecasted Upside/Downside
+293.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-264,520,000.00
Net Margins
-187.70%
Pretax Margin
-188.01%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share

Miscellaneous

Free Float
138,123,000
Market Cap
$179.16 million
Optionable
Optionable
Beta
0.47

Key Executives

  • Mr. Patrick J. Mahaffy MA (Age 55)
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
  • Dr. Gillian C. Ivers-Read BScDr. Gillian C. Ivers-Read BSc (Age 64)
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
  • Mr. Daniel W. Muehl CPA (Age 54)
    Sr. VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Lindsey Rolfe BSc (Age 50)
    MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
  • Mr. Corwin Dale Hooks (Age 51)
    Chief Commercial Officer and Sr. VP













CLVS Stock - Frequently Asked Questions

Should I buy or sell Clovis Oncology stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings
or view top-rated stocks.

What is Clovis Oncology's stock price forecast for 2022?

2 brokers have issued twelve-month price targets for Clovis Oncology's stock. Their CLVS share price forecasts range from $4.75 to $5.00. On average, they expect the company's share price to reach $4.88 in the next year. This suggests a possible upside of 275.0% from the stock's current price.
View analysts price targets for CLVS
or view top-rated stocks among Wall Street analysts.

How have CLVS shares performed in 2022?

Clovis Oncology's stock was trading at $2.71 at the start of the year. Since then, CLVS stock has decreased by 52.0% and is now trading at $1.30.
View the best growth stocks for 2022 here
.

When is Clovis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CLVS earnings forecast
.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Monday, August, 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. During the same quarter in the previous year, the business earned ($0.61) EPS.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How do I buy shares of Clovis Oncology?

Shares of CLVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $1.30.

How much money does Clovis Oncology make?

Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $187.82 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.

This page (NASDAQ:CLVS) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.